Generation Bio Co.

How big is Generation Bio Co.?

As of Jun 18, Generation Bio Co. has a market capitalization of 25.61 million, with net sales of 24.55 million and a net profit of -71.92 million over the last four quarters. Shareholder's funds are 86.20 million, and total assets are 231.20 million as of Dec 24.

As of Jun 18, Generation Bio Co. has a market capitalization of 25.61 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 24.55 million, while the sum of Net Profit for the same period is -71.92 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 86.20 million and Total Assets at 231.20 million.

What does Generation Bio Co. do?

Generation Bio Co. is a genetic medicines company focused on non-viral gene therapies for rare and prevalent diseases, with a market cap of $25.61 million and a quarterly net sales of $9 million. As of March 2025, the company reported a net profit loss of $15 million.

Overview: <BR>Generation Bio Co. is a genetic medicines company in the Pharmaceuticals & Biotechnology industry, focusing on developing non-viral gene therapies for rare and prevalent diseases.<BR><BR>Financial Snapshot: <BR>Net Sales: 9 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -15 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 25.61 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.02 <BR>Return on Equity: -86.41% <BR>Price to Book: 0.35 <BR><BR>Contact Details: <BR>Address: 301 BINNEY STREET, CAMBRIDGE MA: 02142 <BR>Tel: 1 857 5295908 <BR>Fax: 1 302 6555049 <BR>Website: https://generationbio.com/

Should I buy, sell or hold Generation Bio Co.?

Who are in the management team of Generation Bio Co.?

As of March 2022, the management team of Generation Bio Co. includes Jason Rhodes (Independent Chairman), Dr. Cameron McDonough (President and CEO), and four Independent Directors: Gustav Christensen, Dr. Jeffrey Jonas, Dr. Donald Nicholson, and Dr. Anthony Quinn.

As of March 2022, the management team of Generation Bio Co. includes the following individuals:<BR><BR>- Mr. Jason Rhodes, who serves as the Independent Chairman of the Board.<BR>- Dr. Cameron McDonough, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Gustav Christensen, who is an Independent Director.<BR>- Dr. Jeffrey Jonas, who is also an Independent Director.<BR>- Dr. Donald Nicholson, who serves as an Independent Director.<BR>- Dr. Anthony Quinn, who is another Independent Director. <BR><BR>This team comprises a mix of leadership roles and independent directors contributing to the governance of the company.

Is Generation Bio Co. overvalued or undervalued?

As of November 9, 2023, Generation Bio Co. is rated as risky due to significant losses and poor performance metrics, with a negative P/E ratio of -0.6048, indicating overvaluation compared to peers and a year-to-date stock return of -43.58%, significantly underperforming the S&P 500's 12.22% return.

As of 9 November 2023, the valuation grade for Generation Bio Co. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its significant losses and poor performance metrics. Key ratios include a Price to Book Value of 0.40, an EV to EBIT of 1.63, and an EV to EBITDA of 1.75, which suggest that despite low valuations, the company's financial situation remains precarious.<BR><BR>In comparison to its peers, Generation Bio Co. has a negative P/E ratio of -0.6048, while Akebia Therapeutics, Inc. shows a much larger negative P/E of -30.5922, and scPharmaceuticals, Inc. has a P/E of -4.3946. This places Generation Bio in a challenging position within the industry. Additionally, the company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -43.58% compared to the index's 12.22%, reinforcing the notion of overvaluation amidst its financial struggles.

Is Generation Bio Co. technically bullish or bearish?

As of September 2, 2025, Generation Bio Co. is in a mildly bearish trend, with key indicators showing bearish signals despite some bullishness in the MACD and RSI, and it has significantly underperformed the S&P 500 with a year-to-date return of -43.58%.

As of 2 September 2025, the technical trend for Generation Bio Co. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators supporting this view including a mildly bearish daily moving average and a weekly Dow Theory signal also indicating mild bearishness. The MACD shows a mildly bullish signal on both weekly and monthly time frames, but this is countered by a bearish monthly Bollinger Band and a bearish monthly KST. The RSI is bullish on a monthly basis but shows no signal weekly.<BR><BR>In terms of performance, Generation Bio has significantly underperformed the S&P 500 across all observed periods, with a year-to-date return of -43.58% compared to the S&P 500's 12.22%, and a one-year return of -76.91% versus the S&P 500's 17.14%.